Landos Biopharma

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients.

BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that two late-breaking abstracts on preclinical data of omilancor in psoriasis and proof-of concept preclinical data of PX-69 in rheumatoid arthritis will be presented at the upcoming American Association of Immunologists (AAI) Annual Meeting 2021. The meeting will be held virtually from May 10-15, 2021.

Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting

BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tiago Girão to its Board of Directors. Mr. Girão holds over 20 years of experience as a cross-functional leader who has held various positions in finance and operations for U.S. and global private and public life sciences companies.

Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patient dosing in the first half of 2022.

Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation

Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

NX-13 was well tolerated with no reported serious adverse events

Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 2021 at 12:00 PM EST.

Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Angion Biomedica

Atotech

Bolt Biotherapeutics

Immunocore Holdings

Lucira Health

ON24

Pharvaris B.V.

Sana Biotechnology

Sensei Biotherapeutics

Terns Pharmaceuticals

TELUS International (Cda)

Vor Biopharma

The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.

U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week

Three biotechs—Sana Biotechnology, Landos Biopharma, Sensei Biotherapeutics—and chemicals specialist Atotech made their public-market debut Thursday. Here's how they fared.

A Busy Day for Biotech IPOs

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.

Landos Biopharma Announces Pricing of Initial Public Offering

News for Landos Biopharma Stock (LABP)